scorecardresearch
Thursday, July 17, 2025
TopicHaemophilia

Topic: Haemophilia

Govt considers low-dose emicizumab for haemophilia, trial finds it more effective than existing treatment

‘Miracle drug’ can cost Rs 13 lakh for haemophilia A patient annually, but reduced dose found efficacious & cost-effective in small trial. Larger trial is under way.

A new RNA therapy could prevent spontaneous bleeding in haemophiliacs, ‘reduce treatment burden’

Studies in The Lancet & The Lancet Haematology show 1st of its kind preventive therapy by Sanofi, using monthly injection 'fitusiran', can reduce bleeding in haemophilia A or B patients.

New US-approved gene therapy for Haemophilia B world’s most expensive drug — $3.5 mn per dose

Hemgenix, manufactured by Australia's CSL Behring, is a one-time therapy, given through a single dose of IV infusion & was approved by US Food and Drug Administration this week.

‘Bloodbath childhood’ is what I got in India. Haemophilia needs Modi govt’s attention

In India, WHO-recommended 'standard care' is so expensive that many can't afford it. The other option is to simply wait till the bleeding stops.

On Camera

India’s solar ambition needs financial vision – ISA must move from commitments to execution

The ISA should champion a Global Solar Asset Registry for standardised project information, and establish a Solar Credit Guarantee mechanism to mitigate political and currency risks.

India-US set to ink mini trade deal soon, reach understanding on agricultural & dairy products

Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.

3 top ULFA-I leaders ‘killed’ in Myanmar, Indian Army denies role as insurgent group alleges involvement

The banned group claimed their leaders & cadres were killed in ‘drone strikes’ by the Indian Army. Guwahati Defence PRO denies any such operation.

RSS chief Bhagwat draws the line at 75. India’s politics stares at the Modi Exception

BJP has no dynastic succession, at least not at the top. You can trace this back to Vajpayee-Advani era. This act of spotting, empowering younger talent is even more striking with the choice of BJP presidents.